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Summary. Machine Learning methods have of late made significant efforts to solving multi-
disciplinary problems in the field of cancer classification in microarray gene expression data.
These tasks are characterized by a large number of features and a few observations, making
the modeling a non-trivial undertaking. In this work we apply entropic filter methods for gene
selection, in combination with several off-the-shelf classifiers. The introduction of bootstrap
resampling techniques permits the achievement of more stable performance estimates. Our
findings show that the proposed methodology permits a drastic reduction in dimension, of-
fering attractive solutions both in terms of prediction accuracy and number of explanatory
genes; a dimensionality reduction technique preserving discrimination capabilities is used for
visualization of the selected genes.
Key words: Biological data mining and knowledge discovery; Gene expression analysis,
Tools and methods for computational biology and bioinformatics; Cancer informatics.
1 Introduction
In cancer diagnosis, classification of the different tumor types is of great importance. Tra-
ditional methods of tackling the distinction between different types of cancer are primarily
based on morphological characteristics of tumorous tissue [8]. Machine Learning methods are
now extensively used for this task [3]. Typically, a gene expression data set may consist of
dozens of observations with thousands or even tens of thousands of genes. Classifying cancer
types using this very high ratio between number of variables and number of observations is a
delicate process, because of the high risk of overfitting the data. As a result, dimensionality
reduction and in particular feature selection (FS) techniques may be very useful. The finding
of small subsets of very relevant genes among a huge quantity could derive in much specific
and efficient treatments. However, in a FS scenario, gene expression data analysis may entail
a heavy computational consumption of resources, due to the extreme sparseness compared to
standard data sets in classification tasks [34]. For these reasons, in this work we rely on filter
measures for feature selection (that are classifier-independent) in order to keep the computa-
tional cost within reasonable bounds. We are also concerned with increasing the reliability of
the FS process, in the sense of reducing the inherent instability caused by the particular choice
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of data sample. In addition, in order to further reduce the chance of overfitting the data, we
take the decision of using low-complexity classifiers (5 of the 8 used classifiers are linear or
quadratic) together with a small subset of highly relevant genes.
Of special importance in a practical medical setting is the interpretability of the solutions
in terms of the obtained gene subsets. A dimensionality reduction technique that provides a
data projection –while preserving the class discrimination achieved by a classifier– is also
used in our study. Our experimental findings show that the proposed feature selection method-
ology offers highly competitive solutions both in terms of prediction accuracy and number of
explanatory genes. In particular, we report results that offer better performance in both aspects
at least for two of the analyzed microarray tasks. In addition, we provide biological evidence
for the three most important genes obtained in each microarray data set.
2 Feature Selection in the Microarray domain
The Bioinformatics community has recognized the FS process as a key issue in gene expres-
sion data analysis [25]. In many gene selection methods a list of the top ranked genes based on
some merit figure is generated, followed by an inductive step where a classifier is incremen-
tally evaluated on the list [31]. Fisher’s criterion [15], the signal-to-noise ratio [12], the χ2
statistic [23] or Wilcoxon’s rank sum test [9] are popular choices. However, considering indi-
vidual contributions only can very likely hinder the discovery of interactions between genes.
Mutual Information (MI) has been successfully used in FS for measuring the influence
that a feature has over a class or target. Several criteria to evaluate subsets of features employ
it, mostly in the bivariate case, between a feature and the class. A few use a normalized variant
defined by CXY = I(X ;Y )H(Y ) , where Y is the class, I(X ;Y ) = H(Y )−H(Y |X) and H denotes the
entropy. Note that I(X ;X) = H(X), since H(X |X) = 0 and I(X ;Y ) = I(Y ;X). The expression
for CXY , sometimes referred to as the coefficient of constraint, can be better understood by
analyzing Fig. 1 (left). It can be seen that by increasing I(X ;Y ), H(Y |X) decreases; in other
words, there is a reduction in the uncertainty of Y due to the action of X . The maximum value
that I(X ;Y ) could take is H(Y ). This property has been exploited in order to create an index
to measure subsets of features with respect to a class or target value [36]. Alternatively, both
relevance and redundancy of genes has been assessed by using MI, configuring a criterion of
minimum redundancy-maximum relevance (mRMR) [10]. The reader is referred to [25] for a
recent compilation on the use of these measures. The computation of MI can be extended from
the bivariate to the multivariate case, of a number n ≥ 2 of variables against another one, as
I(X1, . . . ,Xn;Y ) = ∑ni=1 I(Xi;Y |X1, . . . ,Xi−1) = H(Y )−H(Y |X1, . . . ,Xn), whereas conditional
MI is expressed in the natural way, as I(X ;Y |Z) = H(Y |Z)−H(Y |X ,Z).
Instead of by conditioning, in this work we propose to calculate the MI between a class
variable Y and two variables X and Z, as shown in Fig. 1 (right). The shaded area represents
I(Y ;X ,Z) = H(Y )+ H(X ,Z)−H(X ,Y,Z), the information that X ,Z explain about Z. Given
that I(Y ;X ,Z) ≤ 1 and that H(Y ) acts as the baseline reference, it is wise to normalize it as
H(Y )+H(X ,Z)−H(X ,Y,Z)
H(Y ) , obtaining an index that evaluates the influence of two variables with
respect to a class. It takes values between zero (no relevance) and one (maximum relevance).
In order for this expression to be of practical use from the FS point of view, it needs to be
extended to the multivariate case. The MI between a subset of variables and the class variable
is computed by generating first a “super-feature”, obtained considering the concatenation of
each combination of possible values of its forming features. In symbols, let X = {X1, ...,Xn}
be the full feature set and consider a subset τ = {τ1, · · · ,τk} ⊆ X . A single feature Vτ can
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Fig. 1. Entropy concepts. Left: Basic Mutual Information. Right: Mutual information between
two variables and class or target variable
be obtained uniquely, whose possible values are the concatenations of all possible values of
the features in τ (for completeness, define V /0 = /0). An index of relevance R of a feature Xi
to a class Y with respect to a subset τ is then given by R(Xi;Y |τ) = H(Y )+H(τ,Xi)−H(τ,Y,Xi)H(Y ) ,
for Xi ∈ X ,τ ⊆ X \Xi. The use of the super-feature allows a faster implementation in case of
discrete variables, whose development is not essential in this context.
To compute the necessary entropies, a discretization process is needed. This change of
representation does not often result in a significant loss of accuracy (sometimes significantly
improves it [27], [30]); it also offers reductions in learning time [7]. In this work, the CAIM
algorithm was selected for two reasons: it is designed to work with supervised data, and does
not require the user to define a specific number of intervals [21]. This way of calculating fea-
ture subset relevance is used to evaluate gene subsets, embedding it into a filter forward-search
strategy, conforming the BGS3 algorithm –standing for Best Gene Subset Search Strategy–, a
supervised filter independent of the search strategy and of the a posteriori inducer, described
in the listing below. This algorithm begins by selecting the feature that maximizes its relevance
with respect to the class feature (lines 1-3). Then a forward search is conducted: at every step,
the feature providing the maximum value of relevance when added to the current subset is
selected (line 6). If, at the end of a step, more that one feature renders the same value for rel-
evance (line 7), the feature that produces the minimum redundancy of information is chosen.
In case the newly added feature brings a benefit, it is added to the current subset (line 9). The
algorithm stops when the index of relevance was not improved, its maximum value has been
reached, or it has run out of features, whichever comes first (line 10).
3 Experimental work
The experimental methodology was aimed to achieve results that reflect the true behavior of
the system as much as possible; in other words, to obtain reliably relevant genes. Bootstrap
resampling techniques are used to yield a more stable and thus more reliable measure of pre-
dictive ability. The original microarray expression data sets S were used to generate B = 5,000
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Algorithm 1: BGS3 Best Gene Subset Search Strategy.
input : X = {X1, . . . ,Xn}: Full gene set; C: Class feature
output: Φ : Best Gene Subset (BGS)
φ ← argmax
f∈X
H(C)−H( f ,C)
H(C)
;
1
Φ ←{φ}: Current best subset;2
R← H(C)−H(Φ ,C)H(C) : Current best relevance;3
exit← f alse;4
repeat5
φ ← argmax
f∈X\Φ
{
H(C)+H(Φ , f )−H(Φ ,C, f )
H(C)
}
;
6
if |φ |> 1 then φ+← argmin
f∈φ
I(Φ , f ) else φ+← φ end;
7
R+← H(C)−H(Φ∪φ
+,C)
H(C) ;8
if R+ > R then R← R+; Φ ←Φ ∪φ+ else exit← true end9
until R+ = 1 ∨ exit ∨ |Φ |= n10
bootstrap samples S1, . . . ,SB that play the role of training sets in the feature selection process:
each relevance value calculated in the algorithm is the average across the B bootstrap samples,
i.e., the average behavior of a feature is used to guide and stabilize the algorithm.
The algorithm is first applied to the discretized bootstrap samples to obtain the Best Gene
Subset or BGS (one for each data set). Then the classifier development stage is conducted
using those original continuous features that are members of their corresponding BGSs. Eight
classifiers were evaluated by means of 10 times of 10-Fold Cross Validation (10x10cv), a
method suitable to handle small sized data sets: the k-nearest-neighbors technique with Eu-
clidean metric (kNN) and parameter k ∈ {1, . . . ,15}, the Naı¨ve Bayes classifier (NB), the
Linear and Quadratic Discriminant classifiers (LDC and QDC), Logistic Regression (LR),
and the Support Vector Machine with linear, quadratic and radial kernels (lSVM, qSVM and
rSVM) and parameter C (regularization constant) (with C = 2k, k running from −7 to 7). The
rSVM has the additional smoothing parameter σ = 2k, k running from −7 to 7).
Validation of the described approach uses five public-domain microarray gene expression
data sets, shortly described as follows: Colon Tumor: 62 observations of colon tissue, of which
40 are tumorous and 22 normal, 2,000 genes [1]. Leukemia: 72 bone marrow observations and
7,129 probes: 6,817 human genes and 312 control genes [12]. The goal is to tell acute myeloid
leukemia (AML) from acute lymphoblastic leukemia (ALL). Lung Cancer: distinction be-
tween malignant pleural mesothelioma and adenocarcinoma of lung [13]; 181 observations
with 12,533 genes. Prostate Cancer: used in [33] to analyze differences in pathological fea-
tures of prostate cancer and to identify genes that might anticipate its clinical behavior; 136
observations and 12,600 genes. Breast Cancer: 97 patients with primary invasive breast carci-
noma; 12,600 genes analyzed.
The results of the FS stage are presented in Table 1. Sizes of final BGSs for each data set
are considerable small (as low as 3 genes in the Leukemia problem); remarkably, in all cases
the maximum relevance is achieved. Computational times are also reported, ranging from few
minutes to several hours –8 hours at most2. These times should be judged taking into account
2 These figures were obtained in a standard x86 machine at 2.666 GHz.
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Table 1. Gene subsets selected by BGS3: |BGS| is their number, Rmax is the final relevance
achieved, and ’CPU time’ indicates total processing time.
Data set |BGS| Rmax CPU time Gene Accession Number (GAN) or Gene name
Colon Tumor 10 1 13 min M26383 M63391 M76378 X12671 J05032 H40095 H43887
R10066 U09564 H40560
Leukemia 3 1 14 min M23197 at X95735 at U46499 at
Lung Cancer 13 1 4 hrs 37957 at 1500 at 36536 at 35279 at 33330 at 39643 at
32424 at 40939 at 33757 f at 33907 at
179 at 39798 at 1585 at
Breast Cancer 16 1 4 hrs AL080059 NM 003258 NM 003239 NM 005192
Contig7258 RC NM 006115 AL137615 Contig38901 RC
AL137514 AF052087 U45975 AF112213 AB037828
NM 005744 NM 018391 NM 003882
Prostate Cancer 21 1 8 hrs 37639 at 37720 at 37366 at 31538 at 37068 at 40436 g at
39755 at 31527 at 1664 at 34840 at 36495 at
33674 at 39608 at 31545 at 914 g at 41288 at 37044 at
40071 at 34730 g at 41732 at 41764 at
that 5,000 resamples for each data set are being processed. The composition of each BGS is
signaled by the gene identifier. These unique IDs will be used to find biological evidence about
the significance of the gene in the disease. Recall that the BGSs are constructed adding at every
step the gene most informative to the current subset, every new set having more informative
power. It seems therefore sensible, in terms of classification performance, to parsimoniously
explore the obtained subsets in an incremental fashion, respecting the order in which the genes
were found –which is the order reported in Table 1.
Table 2. Final accuracy results with comparison to other references. (F) indicates a Filter
algorithm, (W) a wrapper and (FW) a combination of both. Size of the final gene subset and
the used classifier are in brackets.
Colon Lung Breast Prostate
Work Validation Tumor Leukemia Cancer Cancer Cancer
BGS3(F) 10x10cv 89.36 97.89 98.84 83.37 93.43
(9, 3NN) (2, NB) (4, LR) (12, lSV M) (3, 10NN)
[5](F) 200x0.632 88.75 98.2 - - -
bootstrap (14, lSV M) (23, lSV M) - - -
[31](W) 10x10cv 85.48 93.40 - - -
(3, NB) (2, NB) - - -
[37](W) 100xrandom 87.31 - 72.20 - -
subsampling (94, SV M) - (23, SV M) - -
[4](W) 50xholdout 77.00 96.00 99.00 79.00 93.00
(33, rSV M) (30, rSV M) (38, rSV M) (46, rSV M) (47, rSV M)
[17](FW) 10x10cv - - 99.40 - 96.30
- - (135, 5NN) - (79, 5NN)
[16](F) 10cv - 98.6 99.45 68.04 91.18
- (2, SV M) (5, SV M) (8, SV M) (6, SV M)
The accuracy results are presented in Table 2: shown are the final number of genes ob-
tained in the incremental search from the initial BGSs, giving the best 10x10cv accuracy and
the used classifier. To be sure, a non-parametric Wilcoxon signed-rank test is used for the (null)
hypothesis that the median of the differences between the errors of the winner classifiers per
data set and another classifier’s error is zero. This hypothesis can be rejected at the 99% level
in all cases (p-values not shown). It is remarkable that in the Lung Cancer data set, as low as 4
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genes are required to get almost 99% of accuracy. On the other hand, the Breast Cancer data
set is one of the most difficult problems, followed by Colon Tumor (83% and 89%).
It is a common practice to compare to similar works in the literature. Unfortunately, the
methodological steps are in general very different, especially concerning resampling tech-
niques, making an accurate comparison a delicate undertaking. Nonetheless, such a compari-
son is presented in Table 2. Six references which are illustrative of recent work are included.
As stated before, the Colon Tumor data set presents difficulties in classification; however,
BGS3 figures are higher than the rest, even with less genes involved and in front of solutions
that employ a pure wrapper strategy. For the Leukemia data, other references achieve better
figures, some of them using a much bigger gene subset –23 or 30 genes–. Two results report
two genes in their solutions, [31] and [16]. The former does not match the gene subset obtained
by our algorithm, and the latter does not give precise information on the obtained genes. The
Lung Cancer data set is apparently the easiest to separate. Values as high as 99% are achieved
by three of the referenced works, making use of much bigger subset sizes. Incidentally, the
solution in [16] agrees in one gene, the 1500 at WT1-Wilms tumor 1. The solution offered by
BGS3 in the Breast Cancer data set gives the best result among the references, with almost 4%
of difference. The Prostate Cancer data set is well separated by [17], using 79 genes. BGS3
separates it using only two genes, with a degradation of 3% of accuracy. No information is
provided in this reference about which genes are selected. The good performance achieved
with low numbers of selected genes are an indication that these are really good ones in sep-
arating the classes. However, even if interpretable by mere inspection of the involved genes,
the final selection of genes may still provide few clues about the structure of the classes (can-
cer types). Visualization in a low-dimensional representation space may become extremely
important, helping oncologists to gain insights into what is undoubtedly a complex domain.
We use in this work a method based on the decomposition of the scatter matrix -arguably a
neglected method for dimensionality reduction- with the remarkable property of maximizing
the separation between the projections of compact groups of data. This method leads onto the
definition of low-dimensional projective spaces with good separation between classes, even
when the data covariance matrix is singular; further details about this method can be found
in [22]. Such visualization is illustrated by the plots in Fig. 2. These are scatter plots of 2-D
projections of the classes (using the first two eigenvectors of the scatter matrices). In can be
seen that separation is in general quite good (although far from perfect); also, the structure
itself of the two classes provides clues on the variability of each cancer type.
4 Conclusions
Experimental work in comparison to recent works examining the same data sets reveals that
the developed methodology provides very competitive solutions, characterized by small gene
subsets and affordable computational demands. The use of resampling methods to stabilize the
gene selection process –arguably the most delicate part– has shown to deliver final solutions of
very low size and strong relevance. Very noteworthy is the fact that the best classifiers (those
that make good use of the gene subsets found in the feature selection phase) are consistently
very simple: the k-nearest-neighbors technique, Naı¨ve Bayes classifier, Logistic regression
and a linear Support Vector Machine. A final concern has been the practical use of the results
in a medical context, achieved thanks to a dimensionality reduction technique that preserves
the class discrimination capabilities. This joint information may become extremely important
to help oncologists to gain insights into this highly sensitive domain.
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Fig. 2. Visualization of the solutions using the first two eigenvectors of each scatter matrix. In
Colon Tumor and Prostate Cancer circles represent tumorous samples and squares indicates
normal tissue; in Leukemia circles indicate acute lymphoblastic leukemia cells and squares
acute myeloid leukemia cells; in Lung Cancer circles are malignant pleural mesothelioma and
squares areadenocarcinoma; in Breast Cancer circles indicate relapse and squares non-relapse.
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Appendix: Biological evidence
Biological evidence is assembled in the medical literature studying each specific gene. Only
the first (i.e. the more relevant) three genes of each subset are presented, for conciseness.
Colon Tumor: [M26383] IL8-Interleukin 8 encodes a protein member of the CXC chemokine
family and is one of the major mediators of the inflammatory response [26], associated with
a higher likelihood of developing colon tumor recurrence [24]. [M63391] DES-Desmin en-
codes a muscle-specific class III intermediate filament. [19] reported that Interleukin 8 and
Desmin act as the central elements in colon cancer susceptibility. [M76378] CSRP1-Cysteine
and glycine-rich protein 1 may be involved in regulatory processes important for development
and cellular differentiation.
Leukemia: [M23197 at] CD33-CD33 is a putative adhesion molecule of myelomonocytic-
derived cells that is expressed on the blast cells in patients with acute myeloid leukemia [29].
[X95735 at] ZYX-ZYXIN is involved in the spatial control of actin assembly and in the com-
munication between the adhesive membrane and the cell nucleus. This is a gene found in
many cancer classification studies (e.g. [12, 9, 6]) and is highly correlated with acute myel-
ogenous leukemia. [U46499 at] MGST1-Microsomal glutathione S-transferase 1 encodes a
protein thought to protect membranes from oxidative stress and toxic foreign chemicals and
plays an important role in the metabolism of mutagens and carcinogens [26].
Lung Cancer: [37957 at] ATG4-Autophagy related 4 homolog A. Autophagy is activated
during amino-acid deprivation and has been associated with neurodegenerative diseases, can-
cer, pathogen infections and myopathies [32]. [1500 at] WT1-Wilms tumor 1 has an essential
role in the normal development of the urogenital system; this gene is expressed in several can-
cer diseases [2]. [36536 at] SCHIP1-Schwannomin interacting protein 1. The product of the
neurofibromatosis type 2 (NF2) tumour suppressor gene, known as schwannomin or merlin,
is involved in NF2-associated and sporadic schwannomas and meningiomas [14].
Breast Cancer: [AL080059] TSPYL5-TSPY like 5. The gene TSPYL5 encodes testis-
specific Y-like protein but its role in human cancer has not been fully understood. Gene ex-
pression altered by DNA hypermethylation is often associated with cancers. [NM 003258]
TK1-Thymidine kinase 1, soluble is a cytoplasmic enzyme. Studies have shown that in patients
with primary breast cancer, high TK values were shown to be an important risk factor in node-
negative patients and seemed to be associated with beneficial effect of adjuvant chemotherapy
[28]. [NM 003239] TGFB3-transforming growth factor, beta 3 is a potent growth inhibitor
of normal epithelial cells. In established tumor cell systems, however, experimental evidence
suggests that TGF-bs can foster tumorhost interactions that indirectly support the progression
of cancer cells [11].
Prostate Cancer: [37639 at] HPN-Hepsin. Hepsin is a cell surface serine protease and
plays an essential role in cell growth and maintenance of cell morphology and it is highly
related with prostate cancer and benign prostatic hyperplasia. [37720 at] HSPD1-Heat shock
60kDa protein 1 encodes a member of the chaperonin family; [20] established HSPD1 as a
biomarker for prostate malignancy. [37366 at] PDLIM5-PDZ and LIM domain 5. Although
medical evidence for direct implication of PDLIM5 in prostate cancer was not found, it is a
gene recurrently found in several works –e.g. [18].
